AstraZeneca: Long-Term ALPHA Phase III Trial Data Showed Danicopan as Add-On to ULTOMIRIS or SOLIRIS Sustained Clinical Improvements in Subset of Patients With PNH Experiencing Clinically Significant Extravascular Hemolysis
December 11, 2023
December 11, 2023
WILMINGTON, Delaware, Dec. 11 (TNSres) -- AstraZeneca, a biopharmaceutical company, issued the following news release on Dec. 10, 2023:
* * *
Data demonstrated effective control of intravascular and extravascular hemolysis through 48 weeks
Results showed increase in mean hemoglobin levels were maintained through 48 weeks
* * *
Positive results from the 24-week and long-term extension (LTE) period of the pivotal ALPHA Phase III tria . . .
* * *
Data demonstrated effective control of intravascular and extravascular hemolysis through 48 weeks
Results showed increase in mean hemoglobin levels were maintained through 48 weeks
* * *
Positive results from the 24-week and long-term extension (LTE) period of the pivotal ALPHA Phase III tria . . .